Skip to main content

Peer Review reports

From: PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation

Original Submission
28 Sep 2022 Submitted Original manuscript
2 Nov 2022 Reviewed Reviewer Report
31 Dec 2022 Reviewed Reviewer Report
2 Feb 2023 Reviewed Reviewer Report
16 Feb 2023 Author responded Author comments - Bei Lin
Resubmission - Version 2
16 Feb 2023 Submitted Manuscript version 2
4 Mar 2023 Author responded Author comments - Bei Lin
Resubmission - Version 3
4 Mar 2023 Submitted Manuscript version 3
20 Mar 2023 Reviewed Reviewer Report
5 Apr 2023 Author responded Author comments - Bei Lin
Resubmission - Version 4
5 Apr 2023 Submitted Manuscript version 4
26 Apr 2023 Reviewed Reviewer Report
2 May 2023 Reviewed Reviewer Report
15 May 2023 Author responded Author comments - Bei Lin
Resubmission - Version 5
15 May 2023 Submitted Manuscript version 5
22 May 2023 Author responded Author comments - Bei Lin
Resubmission - Version 6
22 May 2023 Submitted Manuscript version 6
24 May 2023 Author responded Author comments - Bei Lin
Resubmission - Version 7
24 May 2023 Submitted Manuscript version 7
Publishing
26 May 2023 Editorially accepted
22 Jun 2023 Article published 10.1186/s12885-023-11017-8

You can find further information about peer review here.

Back to article page